Novel Migraine Prevention Drug Wins FDA Nod
Atogepant (Qulipta) became the first oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for migraine prevention to win FDA approval, AbbVie announced Monday. The drug earned a nod for prevention of episodic migraine in adults and became the second gepant approved for migraine prevention. The first, rimegepant (Nurtec ODT), originally was approved to […]
Long-Acting Injectable for HIV Prevention Passes Hurdles, but Barriers Remain
Long-acting injectable HIV prevention with cabotegravir was superior to daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine (TDF/FTC; Truvada) in men who have sex with men (MSM) and transgender women, a randomized trial found. Among more than 4,500 participants in the phase IIb/III trial, 13 incident infections occurred in the cabotegravir group compared with […]
Trials reveal efficacy and safety of oral drug for treating anemia associated with kidney disease
Pooled results from recent clinical trials indicate that an oral drug called roxadustat is an effective treatment for anemia in patients with chronic kidney disease. The results are published in an upcoming issue of CJASN. Many individuals with kidney dysfunction develop anemia, or a shortage of healthy red blood cells that carry oxygen to the […]
The Pill Can Spell Trouble for Long QTc
Some oral contraceptives were associated with greater cardiovascular risk among women with inherited long QT syndrome (LQTS), a registry study showed. Progestin-only oral contraceptive users had a 2.54-fold higher risk (95% CI 1.09-1.51) of a cardiac event compared with LQTS women not on oral contraceptives in multivariate analysis. Beta-blocker use appeared to mitigate that risk, […]